

Nishan Tchekmedyian, MD

BUSINESS ADDRESS

PACIFIC SHORES MEDICAL GROUP
19582 Beach Blvd., Suite 212
Huntington Beach, CA 92648
Phone: 714-252-9415
Fax: 714-963-8407

www.pacshoresoncology.com

ADDITIONAL OFFICES

Pacific Shores Medical Group
1043 Elm Avenue, Suite 104
Long Beach, CA 90813
Phone: 562-590-0345
Fax: 562-437-8139

Pacific Shores Medical Group
16300 Sand Canyon Avenue, #207
Irvine, CA 92618
Phone: 949-333-7580
Fax: 949-333-7599

CURRENT PRACTICE AFFILIATION

July 2016 – Present Pacific Shores Medical Group

HOSPITAL AFFILIATIONS

Hoag Memorial Hospital (Newport Beach, Irvine), Orange Coast Memorial Medical Center, Saddleback Memorial Medical Center, Long Beach Memorial Medical Center, Los Alamitos Medical Center, St. Mary Medical Center

EDUCATION and TRAINING

2013-2016		Clinical Fellow in Hematology and Oncology H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL University of South Florida
2010 – 2013		Intern and Resident in Internal Medicine Beth Israel Deaconess Medical Center, Boston, MA Clinical Fellow in Medicine, Harvard Medical School
2006-2010	MD	David Geffen School of Medicine at University of California, Los Angeles
2001-2006	BA, BS	University of California, Los Angeles Business Economics; Molecular, Cell, and Developmental Biology

RESEARCH EXPERIENCE

- 2016-Present Pacific Shores Medical Group (Please refer to Clinical Research Experience section)
- 2013-Present Moffitt Cancer Center and Research Institute
Department of Thoracic Oncology, Immunology Program
Mentors: Jhanelle Gray, MD, Eric Haura, MD, and Amer Beg, PhD
Ongoing projects: 1) Utilizing parsimonious digital gene expression profiling (nanoString) to characterize lung cancer immunogenicity in formalin-fixed paraffin-embedded tissue, 2) A phase I/II study of pembrolizumab and vorinostat in patients with immune therapy naïve and immune therapy pretreated advanced NSCLC (Investigator Initiated Trial **NCT02638090**)
- 2011-2013 Beth Israel Deaconess Medical Center, Harvard Medical School
Gynecologic Medical Oncology Program
Mentors: Stephen Cannistra, MD and Panagiotis A. Konstantinopoulos MD, PhD
Area of Concentration Research Project: Utilizing The Cancer Genome Atlas (TCGA): A genomics-based approach for characterizing BRCAness in epithelial ovarian cancer.
- 2011 Research Course, Beth Israel Deaconess Medical Center
Dr. Kenneth Mukamal and Dr. Gordon Strewler
- 2000-2010 Division of Hematology-Oncology, David Geffen School of Medicine at UCLA
Mentors: Dennis J. Slamon, MD, PhD, Richard S. Finn, MD, William Tap, MD, and Melinda S. Epstein, PhD
Projects: 1) Rational Development of anti-Epidermal Growth Factor Receptor Targeted Therapeutics used in the Treatment of Pancreatic Cancer, 2) The role HER-2 and Vascular Endothelial Growth Factor alpha in neo-angiogenesis.

INTERNATIONAL EXPERIENCE

- March-April, 2010 Clinical Elective in Gastroenterology
Hospital de Clínicas, Montevideo, Uruguay,
Facultad de Medicina
Universidad de la República, Uruguay
- July-August, 2006 *Attachment (aka Externship)*
Department of Orthopedic Surgery
Komfo Anokye Teaching Hospital, Kumasi, Ghana.

LEADERSHIP ROLES & SELECTED ACTIVITIES

- 2015: Speaker, FLASCO Fall Session. *New Developments in Lung Cancer*. November 7, 2015, Tampa, Florida.
- 2015: Speaker, Chemical Biology & Molecular Medicine. *Combining small molecules with immune-therapeutics: Bench to Bedside*. August 4, 2015, Moffitt Cancer Center, Tampa, Florida.
- 2014: Panelist, New Frontiers in Urologic Oncology, September 20, 2014, Tampa, Florida
- 2013: Speaker, Internal Medicine Grand Rounds June 13, 2013, Beth Israel Deaconess Medical Center, Harvard Medical School: “Utilizing The Cancer Genome Atlas (TCGA): A genomics-based approach for characterizing BRCAness in epithelial ovarian cancer”
- 2012-2013: BIDMC Journal Club Leader. October 4, 2012 presentation “Onco-Economics: Future supply and demand for oncologists”
- 2007-2010: Member, Committee on Admissions, David Geffen School of Medicine at UCLA
- 2006-2010: Director of Development, Four Pearls of Beckstrand Cancer Foundation

This charitable foundation focuses on allocating funds and running programs to improve and enhance the quality of life of pediatric cancer patients and their families.

- 2006 and 2007: Founder and Student Director, “The Healing Arts: Visual Insights into the Cancer Experience” and “Beyond Words and Time: Women Fight Cancer through Art,” programs of the Simms/Mann Center for Integrative Oncology, part of the Jonsson Comprehensive Cancer Center at UCLA
- “The Healing Arts,” attracted more than 200 people on the opening night and was featured in several periodicals, including the *Los Angeles Times*.

BOOK CHAPTERS

1. **Tchekmedyian N**, Nguyen D, Bello C. (2016, in press). Marginal Zone Lymphoma. In Sallman DA, Chaudhury A, Nguyen J, Zhang L, List AF (Ed.), *Handbook of Hematologic Malignancies*. New York, New York: Demos Medical.
2. Gupta R, Mastrodomenico M, **Tchekmedyian N**, Chhabra S. (2016, in press). Mucosa-Associated Lymphoid Tissue Lymphoma. In Sallman DA, Chaudhury A, Nguyen J, Zhang L, List AF (Ed.), *Handbook of Hematologic Malignancies*. New York, New York: Demos Medical.

PUBLICATIONS

1. **Tchekmedyian N**, Ali SM, Miller VA, Haura EB. Acquired ALK L1152R Mutation Confers Resistance to Ceritinib and Predicts Response to Alectinib. *Journal Thoracic Oncology*. Manuscript accepted for publication on March 29, 2016.
2. **Tchekmedyian N**, Gray JE, Creelan BC, Chiappori AA, Beg AA, Soliman H, Perez BA, Antonia, SJ. Propelling Immunotherapy Combinations Into the Clinic. *Oncology (Williston Park)*, 29(12). 2015.
3. Benz MR, **Tchekmedyian N**, Eilber FC, Federman N, Czernin J, Tap WD. Utilization of positron emission tomography in the management of patients with sarcoma. *Current Opinion in Oncology*. 21(4); 345-351. 2009.
4. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, **Tchekmedyian N**, Slamon DJ. Dasatinib, an orally active small molecule inhibitor of both the *src* and *abl* kinases, selectively inhibits growth of basal-type/“triple negative” breast cancer cell lines growing in vitro. *Breast Cancer Research and Treatment*. 105(3): 319-326. 2007.
5. Ucar K and **Tchekmedyian N**. Book Review, “Cancer: What Causes it, What Doesn’t”. *Cancer Treatment Today*. Pg. 10. 2003.

HONOR’S THESIS

1. **Tchekmedyian N**. “Rational Development of anti-Epidermal Growth Factor Receptor Targeted Therapeutics used in the Treatment of Pancreatic Cancer”. Department of Molecular, Cell and Developmental Biology, UCLA. 2005.

ABSTRACTS

1. **Tchekmedyian N**, Mudad R, Haura EB, Blanco FF, Raymond VM, Erlander M, Berz D. Longitudinal monitoring of dynamic changes in urinary ctDNA mutation burden correlate with response to EGFR TKIs. Submitted; World Conference Lung Cancer IASLC December, 2016. Vienna, Austria.
2. **Tchekmedyian N**, Zheng H, Beg AA, Haura EB, Chen DT, Antonia SJ, Gray J. Preclinical rationale for a phase I/II study of pembrolizumab (P) and vorinostat (V) in immune therapy naïve and pretreated Stage IV NSCLC. MINI02.07-Immunotherapy. Mini Oral Presentation World Conference Lung Cancer IASLC Sept, 2015. Denver, Colorado.
3. **Tchekmedyian N**, Zheng H, Beg AA, Haura EB, Chen DT, Antonia SJ, Gray J. Trial in Progress: A phase I/II study of pembrolizumab (P) and vorinostat (V) in patients with immune therapy naïve and immune therapy pretreated Stage IV NSCLC. 2015 Moffitt Scientific Symposium. May, 2015.
4. **Tchekmedyian N**, Morse A, Srisowmya S, Cannistra SA, Konstantinopoulos PA. Association of a BRCAness profile with outcome and molecular aberrations involving homologous recombination in the TCGA ovarian cancer dataset. American Association for Cancer Research Annual Meeting, Chicago, Abstract 2981. 2012.

5. **Tchekmedyian N**, Finn RS, Glaspy P, Venkatesan N, Slamon DJ. Preclinical studies of the EGFR tyrosine kinase inhibitor erlotinib (OSI-774, Tarceva) and 5-fluorouracil in human pancreatic cancer cell lines exhibit synergy and explain possible mechanism of action through thymidylate synthase. West Coast Biological Sciences Undergraduate Research Conference, Santa Clara University. Abstract and Presentation. 2005.
6. Finn RS, Dering J, Wilson CA, Glaspy P, **Tchekmedyian N**, Yang G, Clark E, Mauro D, Blackwood-Chirchir A, Lee F, Slamon DJ. Biologic effects and identification of predictive markers of response to dasatinib (BMS-354825), a novel, oral multi-targeted kinase inhibitor in human breast cancer cell lines *in vitro*. UCLA Department of Medicine Research Day. 2005.
7. Finn RS, Wilson CA, Venkatesan N, Sanders J, Chen J, Dehring J, Glaspy P, **Tchekmedyian N**, Cook A, Olson T, Slamon DJ. Growth inhibition of human breast cancer cell lines by the EGFR tyrosine kinase inhibitor gefitinib (Iressa™) does not correlate with inhibition of baseline or ligand induced phosphorylation of EGFR, AKT, MAP kinase, or Ras activation. American Association for Cancer Research Molecular Targets and Cancer Therapeutics Meeting. Abstract A90. 2003.
8. Finn RS, Wilson CA, Sanders J, Cook A, Olson T, Glaspy P, **Tchekmedyian N**, Pegram MD, Britten C, Slamon DJ. Targeting the epidermal growth factor receptor and HER-2 with OSI-774 and trastuzumab, respectively, in HER-2 overexpressing human breast cancer cell lines results in a therapeutic advantage in vitro. American Society for Clinical Oncology (ASCO). Abstract 22.940. 2003.
9. Epstein M, Ayala R, **Tchekmedyian N**, Barnstorm P, Pegram M, Slamon D. HER-2 overexpressing human breast cancer xenografts exhibit increased angiogenic potential mediated by vascular endothelial growth factor (VEGF). San Antonio Breast Cancer Symposium. Abstract 570. 2002.

CLINICAL RESEARCH EXPERIENCE

A Phase I/II Study of XXXXXXXXXXXX and XXXXXXXXXXXX in Patients With Immune Therapy Naïve and Immune Therapy Pretreated Stage IV NSCLC

FROM: <https://clinicaltrials.gov/ct2/show/NCT02638090> NCT02638090 (**NCT02638090**)

COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of XXXXXXXXXXXX (XXXXXX) in Combination With XXXXXXXXXXXX for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease

FROM: <https://clinicaltrials.gov/ct2/show/NCT02941926> (IDENTIFICATION NUMBER **NCT02941926**)

A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of XXXX/X Therapy/XXXXXXXXXXXXXXXX

FROM: <https://clinicaltrials.gov/ct2/show/NCT03050398> (IDENTIFICATION NUMBER **NCT03050398**)

A Phase II, Multicenter Study of Oral XXXX Inhibitor XXXXXX in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC)

FROM: <https://clinicaltrials.gov/ct2/show/NCT02414139> (IDENTIFICATION NUMBER **NCT02414139**)

Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of XXXXXXXXXXXX Combined with XXXXXXXXXXXXX in Participants With Advanced or Metastatic Solid Tumors

FROM: <https://clinicaltrials.gov/ct2/show/NCT03098550> (IDENTIFICATION NUMBER **NCT03098550**)

Phase 3b/4 Safety Trial of XXXXXXXXXXXX Combined With XXXXXXXXXXXXX in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivolumAb Clinical Trial Evaluation 920)

FROM: <https://clinicaltrials.gov/ct2/show/NCT02982954> (IDENTIFICATION NUMBER **NCT02982954**)

Randomized, Open-label, Phase 3 Trial of XXXXXXXXXXXX Plus XXXXXXXXXXXXX XXXXXXXX Versus XXXXXXXXXXXX XXXXXXXX Alone in Participants With Relapsed Refractory or Ineligible for Autologous Stem

Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma (CheckMate: CHECKpoint Pathway and nivolumAb Clinical Trial Evaluation 812)

FROM: <https://clinicaltrials.gov/ct2/show/NCT03138499> (IDENTIFICATION NUMBER **NCT03138499**)

PERSONAL INTERESTS

Running half-marathons, Latin ballroom dancing, yoga, kayaking, travel to Uruguay, making and eating an excellent asado, and coffee.

LANGUAGES

Fluency in English, Spanish, and Armenian

HONORS AND AWARDS

- **Highly Rated Poster**, American Association of Cancer Research Annual Meeting, Chicago (2012)
- **Wings of Honor Alumni Award**, The Pegasus School, California (2011)
- **Outstanding Senior Award**, granted to one graduating senior in Molecular, Cell and Developmental Biology at UCLA for academic, research, and community accomplishments (June 2006)
- **Highest Honors in Molecular, Cell and Developmental Biology at UCLA** (June 2006)
- **Dean's Prize, Outstanding Research Presentation**, Annual UCLA Science Poster Day (May 2005)
- **UCLA Finalist, Council on Undergraduate Research: Posters on Capitol Hill** (March 2005)
- **Howard Hughes Research Program Fellowship / Merit Scholarship**, UCLA (Fall 2003-2006)